Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUY922 weekly IV dose-escalation and breast cancer expansion study
NL-OMON32784Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of Luminespib in Nonhematologic neoplasms and breast cancer (3 arms), sponsored by Novartis. Primary endpoints: Maximum tolerated dose and Clinical response classification. Started Dec 2008; status: active, not recruiting.
02
Drugs
Luminespib
03
Conditions
Nonhematologic neoplasmsbreast cancer
Beyond the preview
Go deeper on NL-OMON32784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32784.